Crinetics Raises $350 Million to Accelerate Development of Novel Therapies for Rare Endocrine Diseases and Oncology

Crinetics Pharmaceuticals, a clinical-stage biopharmacutical company based in San Diego, California, recently announced that it has successfully closed a $350 million private funding round. This round of financing consists of a series of well-known institutions and investors get health care, Including the Adage Capital Partners L.P, Driehaus Capital Management, EcoR1 Capital, First Light Asset Management, Gordon Global Investments LP, Invus, Janus Henderson Investors, lot BioCapital, Perceptive Advisors and Rock Springs, Capital, etc.

Founded in 2008 by Dr. Scott Struthers, the company is focused on the development of new therapies for rare endocrine diseases and endocrin-related cancers. Crinetics research has uncovered critical roles in regulating human physiological processes for more than 130 peptide hormone receptors that are frequently overexpressed in a variety of cancers.

Crinetics plans to use its proprietary technology platform development can with the small molecules of these receptors, to guide positioning directly to the cancer cells, radioactive isotope for PET imaging or targeted radiotherapy, thus improve the therapeutic effect.

In October 2021, Crinetics with 5 am Ventures and Frazier Healthcare Partners cooperation set up independent company Radionetics Oncology. Radionetics Oncology Crinetics radiotherapy technology platform of global exclusive authorization, and raised $30 million in the first round of financing. In June 2024, Radionetics Oncology established strategic cooperative relations with lilly, lilly will provide $140 million advance payment, in order to promote to g protein coupled receptor for the development of small molecule radioactive ligand therapy. Lilly also received up to $1 billion to buy related chemical derivatives of the option.

Crinetics' own pipeline is focused on rare endocrine diseases and endocrin-related cancers, with its lead candidate, CRN00808, a somatostatin receptor type 2 (SSTR2) agonist, currently in clinical trials for acromegaly and neuroendocrine tumors and expected to enter commercialization as early as next year.

The $350 million financing will be used to accelerate the development of clinical-stage drug candidates, support research programs, and strengthen the company's overall operations and general corporate strategy. As of July 31, 2024, the company a market capitalisation of $41.89 billion, is expected to reach $538.5 billion in predicts 2030, the compound annual growth rate of 7.34%, the rapid growth of endocrine therapy in the market, meet the unsatisfied demand more.